Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Name: Kaimen Rigor review — Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Item: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Rating: 59
Author: Alpha1

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL

Paper source

Read full text (PMC)PDF

Embed this Rigor badge

Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 5 high issues for “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL

Read full text (PMC)

Open PDF

DOI

10.1001/jama.2025.20620

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/459d1cda-9d3e-46e2-8dbe-a9975a5a4bf6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/459d1cda-9d3e-46e2-8dbe-a9975a5a4bf6/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 5 high issues for “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

412bb9b831d9a989084987ee70f9e7ee801a01d632294303529a3c51d869693b

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL

Paper source

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Read full text (PMC)PDF

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is the percentage change in LDL-C level, a surrogate biomarker for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking LDL-C reduction to clinical outcomes in this specific context.
“The primary outcome was the mean percentage change in LDL-C level at week 24.”

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with a clear premise, rigorous design, and appropriate statistical analysis. The main weaknesses are missing explicit ethics approval and informed consent statements, an incomplete data sharing statement, and a few minor reporting gaps (e.g., statistical software, randomization method, power analysis).

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered the abstract and methods/results sections; some details (e.g., full data sharing statement, ethics approval) were not available in the provided text. The statistics verification checked 5 reported tests, all consistent, but this does not confirm the entire statistical analysis.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

2 findings · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

Eight Dimensions6 pass · 2 warn

The introduction cites the increased cardiovascular risk in HeFH and the failure of many patients to achieve LDL-C goals with current therapies, establishing the need for new treatments. The objective directly follows from this premise. The paper does not explicitly discuss limitations of prior research, but the premise is well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing the unmet need in HeFH and prior research on PCSK9 inhibitors, and provides a logical rationale for the study.

Evidence

“Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.”

Introduction

“To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy.”

Introduction

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise: HeFH patients have elevated LDL-C and many do not achieve goals with current therapies, justifying evaluation of a new oral PCSK9 inhibitor.

Evidence

“Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.”

Introduction

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Randomization method is not explicitly described (e.g., computer-generated), but the trial is described as randomized and double-blind. The unit of randomization is the participant. Blinding is stated (double-blind). A power analysis is not reported, but the sample size is large and the effect size is large. Inclusion/exclusion criteria are clearly defined. The analysis population (modified intention-to-treat) is described, addressing missing data. The placebo control is appropriate.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a pre-specified primary endpoint and appropriate statistical analysis.

Evidence

“This phase 3, randomized clinical trial”

Abstract

“included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease.”

Methods

“The primary outcome was the mean percentage change in LDL-C level at week 24.”

Methods

PASSReviewer 2· 95% conf

The trial is well-designed: randomized, double-blind, placebo-controlled, with a pre-specified primary outcome and adequate sample size.

Evidence

“This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease.”

Abstract

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Power analysis is not reported.

The paper reports mean age, sex distribution, and baseline LDL-C levels. It does not report race/ethnicity or comorbidities in the abstract, but these are likely in the full results. Since both sexes are enrolled, sex justification is not applicable.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are reported, including age, sex, and lipid levels.

Evidence

“mean age, 52.4 [SD, 13.5] years; 51% were female”

Abstract

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline”

Abstract

absence[Abstract]

Race/ethnicity and comorbidities are not reported in the abstract.

PASSReviewer 2· 90% conf

Key biological variables (sex, age, baseline LDL-C) are reported; demographics are adequate for a human trial.

Evidence

“Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial.”

Results ¶1

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe.”

Results ¶1

The paper is a clinical trial involving human participants, so ethics approval and informed consent are required. The abstract and methods do not mention an IRB or ethics committee approval, nor informed consent. The trial registration number is provided, which implies ethical oversight, but the explicit statement is missing.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a clinical trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

“ClinicalTrials.gov Identifier: NCT05952869”

Abstract

WARNReviewer 2· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

The drug enlicitide decanoate is named, and the dose (20 mg) is given. The manufacturer is implied (Merck). However, the formulation and lot numbers are not provided, which is typical for a clinical trial. No other biological resources are used.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drug (enlicitide) is identified, and the trial is a drug trial, so the drug is the key resource.

Evidence

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 85% conf

The investigational product (enlicitide) is identified, and the trial is scored on that basis.

Evidence

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Statistical software is not identified.

The primary analysis uses a mixed model for repeated measures, which is appropriate. Tests are not explicitly named but the model is described. Exact p-values are reported (P < .001). Effect sizes with 95% CIs are reported. Statistical software is not identified. Data presentation includes per-group n and CIs. Mathematical plausibility is not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedINADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and results are reported with confidence intervals and p-values.

Evidence

“between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001”

Abstract

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and p-values are exact. The analysis is appropriate for a clinical trial.

Evidence

“The mean percentage change in LDL-C level at week 24 was −58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001).”

Results ¶2

absence[Methods]

Statistical software is not identified.

The paper mentions a 'Data Sharing Statement: See .' but the actual statement is not included in the provided text. This is vague and does not specify a concrete access route. No data repository or code repository is mentioned.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

“Data Sharing Statement: See .”

Article Information

absence[Full text]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

“Data Sharing Statement: See .”

Data availability

The trial is registered with ClinicalTrials.gov. Methods are described in sufficient detail. The reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting. All outcomes are reported. Limitations are not explicitly discussed in the abstract, but likely in the full text. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedNOT REPORTED

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are described, and conclusions are proportional to the results.

Evidence

“ClinicalTrials.gov Identifier: NCT05952869”

Abstract

paraphrase[Article Information]

“Funding/Support: Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

absence[Abstract]

Limitations are not discussed in the abstract.

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, and conclusions are proportional. Limitations are not explicitly discussed, but the paper is otherwise transparent.

Evidence

“Trial Registration ClinicalTrials.gov Identifier: NCT05952869”

Abstract

paraphrase[Article Information (Funding/Support and Conflict of Interest Disclosures)]

“Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 1 reference by DOI: 1 verified.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but an informed reader should weigh the missing explicit ethics approval and informed consent statements, and the incomplete data sharing statement. These are reporting gaps that could warrant a correction or clarification from the authors, but they do not undermine the validity of the trial results.

1.
HIGHethics
Add an explicit ethics approval statement in the Methods section, naming the IRB/ethics committee and approval number, and a statement on informed consent.
A clinical trial must document ethics approval and informed consent; its absence is a serious reporting gap that could trigger a correction.
2.
HIGHdata code
Provide the full data sharing statement in the manuscript, specifying how to access the data (e.g., via a data-sharing platform or on request with conditions).
The current statement is incomplete ('See .'), which fails to meet transparency requirements for a data-driven trial.
3.
HIGHreporting
Add a limitations section in the Discussion, addressing potential biases, generalizability, and missing data handling.
Limitations are not explicitly discussed, which is expected in a clinical trial report and helps readers interpret the findings.
4.
HIGHstatistics
Identify the statistical software used for analysis (e.g., SAS version) in the Methods.
Reporting the software is a standard requirement for reproducibility.
5.
HIGHreporting
Mention adherence to CONSORT reporting guidelines in the Methods or as a footnote.
Explicitly stating CONSORT adherence is expected for randomized trials.
6.
MEDIUMrigor
Describe the randomization method (e.g., computer-generated random sequence) and allocation concealment in the Methods.
The randomization method is not described, which is a minor but important methodological detail.
7.
MEDIUMrigor
Report the power analysis or sample size calculation in the Methods to justify the sample size.
A power analysis is not reported, which is a common expectation for clinical trials.
8.
MEDIUMstatistics
Include a statement on how outliers or missing data were handled in the statistical analysis.
Outlier handling is not explicitly described, which is a minor reporting gap.
9.
LOWcopyedit
Clarify the sentence in the Abstract about trial conduct: 'The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025.'
Minor style issue for clarity.

Full text (10,156 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL

Read full text (PMC)

Open PDF

DOI

10.1001/jama.2025.20620

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/459d1cda-9d3e-46e2-8dbe-a9975a5a4bf6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/459d1cda-9d3e-46e2-8dbe-a9975a5a4bf6/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 5 high issues for “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

412bb9b831d9a989084987ee70f9e7ee801a01d632294303529a3c51d869693b

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is the percentage change in LDL-C level, a surrogate biomarker for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking LDL-C reduction to clinical outcomes in this specific context.
“The primary outcome was the mean percentage change in LDL-C level at week 24.”

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit3 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

1 finding · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

2 findings · worst medium

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

Eight Dimensions6 pass · 2 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing the unmet need in HeFH and prior research on PCSK9 inhibitors, and provides a logical rationale for the study.

Evidence

“Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.”

Introduction

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise: HeFH patients have elevated LDL-C and many do not achieve goals with current therapies, justifying evaluation of a new oral PCSK9 inhibitor.

Evidence

Introduction

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a pre-specified primary endpoint and appropriate statistical analysis.

Evidence

“This phase 3, randomized clinical trial”

Abstract

Methods

“The primary outcome was the mean percentage change in LDL-C level at week 24.”

Methods

PASSReviewer 2· 95% conf

The trial is well-designed: randomized, double-blind, placebo-controlled, with a pre-specified primary outcome and adequate sample size.

Evidence

Abstract

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Power analysis is not reported.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are reported, including age, sex, and lipid levels.

Evidence

“mean age, 52.4 [SD, 13.5] years; 51% were female”

Abstract

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline”

Abstract

absence[Abstract]

Race/ethnicity and comorbidities are not reported in the abstract.

PASSReviewer 2· 90% conf

Key biological variables (sex, age, baseline LDL-C) are reported; demographics are adequate for a human trial.

Evidence

“Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial.”

Results ¶1

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe.”

Results ¶1

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a clinical trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

“ClinicalTrials.gov Identifier: NCT05952869”

Abstract

WARNReviewer 2· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drug (enlicitide) is identified, and the trial is a drug trial, so the drug is the key resource.

Evidence

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 85% conf

The investigational product (enlicitide) is identified, and the trial is scored on that basis.

Evidence

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

Methods

absence[Methods]

Statistical software is not identified.

Sub-criteria

tests namedINADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and results are reported with confidence intervals and p-values.

Evidence

“between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001”

Abstract

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and p-values are exact. The analysis is appropriate for a clinical trial.

Evidence

Results ¶2

absence[Methods]

Statistical software is not identified.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

“Data Sharing Statement: See .”

Article Information

absence[Full text]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

“Data Sharing Statement: See .”

Data availability

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedNOT REPORTED

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are described, and conclusions are proportional to the results.

Evidence

“ClinicalTrials.gov Identifier: NCT05952869”

Abstract

paraphrase[Article Information]

“Funding/Support: Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

absence[Abstract]

Limitations are not discussed in the abstract.

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, and conclusions are proportional. Limitations are not explicitly discussed, but the paper is otherwise transparent.

Evidence

“Trial Registration ClinicalTrials.gov Identifier: NCT05952869”

Abstract

paraphrase[Article Information (Funding/Support and Conflict of Interest Disclosures)]

“Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 1 reference by DOI: 1 verified.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHethics
Add an explicit ethics approval statement in the Methods section, naming the IRB/ethics committee and approval number, and a statement on informed consent.
A clinical trial must document ethics approval and informed consent; its absence is a serious reporting gap that could trigger a correction.
2.
HIGHdata code
Provide the full data sharing statement in the manuscript, specifying how to access the data (e.g., via a data-sharing platform or on request with conditions).
The current statement is incomplete ('See .'), which fails to meet transparency requirements for a data-driven trial.
3.
HIGHreporting
Add a limitations section in the Discussion, addressing potential biases, generalizability, and missing data handling.
Limitations are not explicitly discussed, which is expected in a clinical trial report and helps readers interpret the findings.
4.
HIGHstatistics
Identify the statistical software used for analysis (e.g., SAS version) in the Methods.
Reporting the software is a standard requirement for reproducibility.
5.
HIGHreporting
Mention adherence to CONSORT reporting guidelines in the Methods or as a footnote.
Explicitly stating CONSORT adherence is expected for randomized trials.
6.
MEDIUMrigor
Describe the randomization method (e.g., computer-generated random sequence) and allocation concealment in the Methods.
The randomization method is not described, which is a minor but important methodological detail.
7.
MEDIUMrigor
Report the power analysis or sample size calculation in the Methods to justify the sample size.
A power analysis is not reported, which is a common expectation for clinical trials.
8.
MEDIUMstatistics
Include a statement on how outliers or missing data were handled in the statistical analysis.
Outlier handling is not explicitly described, which is a minor reporting gap.
9.
LOWcopyedit
Clarify the sentence in the Abstract about trial conduct: 'The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025.'
Minor style issue for clarity.

Full text (10,156 chars)Analyzed: Aug 15, 2026